MCK vs. CAH: Which Drug Distribution Giant Has the Healthier Outlook?

McKesson (MCK) and Cardinal Health (CAH), both major healthcare distributors, reported strong earnings, with McKesson's Q4 2025 adjusted EPS beating estimates by 3.2% and Cardinal Health's Q3 2025 adjusted EPS beating by 9.3%. McKesson is favored due to its diversification into higher-margin areas and stronger sales and EPS growth estimates, while Cardinal Health focuses on revitalizing its business model through cost controls and expansion of its medical segment; year-to-date, McKesson shares have risen 25.7% and Cardinal Health 29.2% amid rising demand for drug retailing.

Analysis

McKesson (MCK) and Cardinal Health (CAH), prominent U.S. healthcare distributors, both reported strong recent earnings, outperforming consensus estimates. McKesson's fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $10.12 represented a 3.2% beat and a significant 63.8% year-over-year increase, driven by strength in its core pharmaceutical distribution business, expansion of its Oncology platform, and growth in differentiated biopharma solutions. In contrast, Cardinal Health's third-quarter fiscal 2025 adjusted EPS of $2.35 exceeded estimates by 9.3%, with a 12.4% year-over-year improvement, primarily attributed to strong demand for its Pharmaceutical and Specialty solutions. Looking ahead, Zacks Consensus Estimates project robust growth for MCK in fiscal 2026, with sales and EPS expected to rise 12.4% and 12.3% respectively, and its EPS estimates have seen a 1.4% upward revision in the past 60 days. Cardinal Health's fiscal 2025 outlook is more mixed, with an anticipated 1.7% sales decline alongside a 7.8% EPS improvement, though its EPS estimates have improved 2.3% in the last 30 days. McKesson's strategic diversification into higher-margin areas such as oncology, biopharma services, and healthcare technology solutions, coupled with consistent share repurchases and dividend increases, underpins its favorable outlook despite regulatory risks surrounding drug pricing. Cardinal Health is focused on a strategic transformation involving efficiency gains, cost controls, and expansion of its higher-growth medical segment to revitalize its business model, which has shown early positive results in revenue growth and profitability. Year-to-date, both stocks have demonstrated impressive performance, with CAH shares up 29.2% and MCK up 25.7%, partly fueled by increasing demand for drug retailing, including GLP-1 drugs. However, McKesson's 'A' Zacks Style Score, indicating strong growth prospects and attractive valuation, contrasts with Cardinal Health's 'C' score, which reflects attractive valuation but lower growth potential, positioning MCK as the comparatively stronger investment based on these metrics and its superior sales and EPS growth estimates.

Key Decisions for Investors

• Investors should note McKesson's stronger projected sales and EPS growth for fiscal 2026, alongside its strategic diversification into higher-margin segments, which are key differentiators within the drug distribution sector.
• While Cardinal Health's turnaround efforts and recent robust earnings beat are positive, its projected fiscal 2025 sales decline and lower Zacks-rated growth potential compared to McKesson warrant careful monitoring of its strategic execution, particularly in cost-saving initiatives and medical segment expansion.
• Given that both companies face potential regulatory headwinds from drug pricing and reimbursement policies, investors should remain vigilant regarding policy developments that could impact profitability, despite the current positive industry sentiment and strong share performance driven by underlying demand, including for GLP-1 drugs.